Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01631201 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

A Phase 2 study of Chlamydia Trachomatis Infection, sponsored by ActivBiotics Pharma.

Completed
Registry status
Phase 2
Development phase
82
Enrollment target
5
Study locations

NCT01631201 is a Phase 2 study of Chlamydia Trachomatis Infection that has completed, run by ActivBiotics Pharma. The registered enrollment target is 82 participants, below the 1,173-participant average among 3 other Chlamydia Trachomatis Infection trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01631201, a Phase 2 study of Chlamydia Trachomatis Infection, has completed, sponsored by ActivBiotics Pharma.

COMPLETED
Registry status
Phase 2
Development phase
82 participants
Enrollment target
5
Study locations

Study Summary

This study will test the safety and effectiveness of an investigational antibiotic drug, rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1 gram, which will be given as a single dose to women who have genital chlamydial infection.

Conditions Studied

Chlamydia Trachomatis Infection

Interventions

  • DRUG Rifalazil 25 milligram
  • DRUG Azithromycin 1 gram

Study Locations (5)

Alabama

  • Research Site - Birmingham

California

  • Research Site - San Diego

Indiana

  • Research Site - Indianapolis

Nevada

  • Research Site - Las Vegas

Virginia

  • Research Site - Virginia Beach

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2012-07
Est. Completion 2013-04
Phase Phase 2

Sponsor

ActivBiotics Pharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01631201

The ClinicalTrials.gov registry entry for NCT01631201 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,173-participant average among 3 other Chlamydia Trachomatis Infection trials with a reported enrollment target (93% lower). The listed sponsor is ActivBiotics Pharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chlamydia Trachomatis Infection appearing as the primary indexed condition, and to 2 interventions - of which Rifalazil 25 milligram is the first listed.

NCT01631201 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT01631201 about?

NCT01631201 is a clinical study titled "Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women". This study will test the safety and effectiveness of an investigational antibiotic drug, rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1 gram, which will be given as a ...

What is the current status of trial NCT01631201?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2012-07. Estimated completion is 2013-04.

What conditions does trial NCT01631201 study?

This clinical trial studies the following conditions: Chlamydia Trachomatis Infection.

What interventions are being tested in trial NCT01631201?

The interventions under investigation include: Rifalazil 25 milligram (DRUG), Azithromycin 1 gram (DRUG).

Who is sponsoring clinical trial NCT01631201?

This trial is sponsored by ActivBiotics Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01631201 being conducted?

This trial has 5 study locations across Alabama, California, Indiana, Nevada, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chlamydia Trachomatis Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chlamydia Trachomatis Infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.